Vericel to Present at Needham Healthcare Conference
April 08 2015 - 4:01PM
Vericel Corporation (Nasdaq:VCEL), a leading developer of
patient-specific expanded cellular therapies for the treatment of
severe diseases and conditions, today announced that it will
present a corporate update at the 14th Annual Needham Healthcare
Conference at 4:20 pm Eastern time on Wednesday, April 15, at the
Westin Grand Central Hotel in New York. A live webcast of the
presentation will be accessible through the news and events section
of the company's website or can be accessed here:
http://wsw.com/webcast/needham71/vcel/
About Vericel Corporation
Vericel Corporation (formerly Aastrom Biosciences, Inc.) is a
leader in developing patient-specific expanded cellular therapies
for use in the treatment of patients with severe diseases and
conditions. The company markets two autologous cell therapy
products in the United States: Carticel® (autologous cultured
chondrocytes), an autologous chondrocyte implant for the treatment
of cartilage defects in the knee, and Epicel® (cultured epidermal
autografts), a permanent skin replacement for the treatment of
patients with deep-dermal or full-thickness burns comprising
greater than or equal to 30 percent of total body surface area.
Vericel is also developing MACI™, a third-generation
autologous chondrocyte implant for the treatment of cartilage
defects in the knee, and ixmyelocel-T, a patient-specific
multicellular therapy for the treatment of advanced heart failure
due to ischemic dilated cardiomyopathy. For more information,
please visit the company's website at www.vcel.com.
CONTACT: Chad Rubin
The Trout Group
crubin@troutgroup.com
(646) 378-2947
or
Lee Stern
The Trout Group
lstern@troutgroup.com
(646) 378-2922
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Apr 2023 to Apr 2024